Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

SEHK:6990
SEHK:6990Biotechs

Is New Long‑Acting Atopic Dermatitis Antibody IND Approval Altering The Investment Case For Kelun-Biotech (SEHK:6990)?

On 9 March 2026, Kelun-Biotech and Harbour BioMed announced that China’s NMPA approved the IND application for SKB575/HBM7575, a long-acting bispecific antibody for atopic dermatitis with a dual TSLP-based mechanism and extended half-life enabling subcutaneous dosing. This IND approval highlights Kelun-Biotech’s growing capabilities in innovative biologics and positions SKB575/HBM7575 as a potentially differentiated long-interval therapy candidate in atopic dermatitis. We will now examine...
NasdaqGS:INCY
NasdaqGS:INCYBiotechs

Is It Time To Reassess Incyte (INCY) After Recent Share Price Pullback?

If you are wondering whether Incyte at around US$92.54 is offering good value or asking too much, you are not alone. This article is written for that exact question. The share price has seen mixed moves, with a 3.5% decline over the last 7 days and an 8.5% decline over the past month, alongside longer term returns of 36.4% over 1 year, 25.7% over 3 years and 16.6% over 5 years. Recent attention on Incyte has been shaped by ongoing product and pipeline updates, regulatory milestones and...
NasdaqGS:CDXS
NasdaqGS:CDXSLife Sciences

Codexis (CDXS) Is Up 30.9% After Merck-Fueled Q4 Profit Beat And 2026 Revenue Guidance - Has The Bull Case Changed?

In March 2026, Codexis reported fourth-quarter 2025 results showing revenue of US$38.92 million and net income of US$9.6 million, reversing a prior-year loss and beating analyst expectations, alongside full-year 2025 revenue of US$70.39 million and guidance for 2026 revenue of US$72 million to US$76 million. The quarter was heavily influenced by a large technology transfer agreement with Merck and growing ECO Synthesis platform activity, which also underpins management’s view that existing...
TSX:LIF
TSX:LIFMetals and Mining

Assessing Labrador Iron Ore Royalty (TSX:LIF) Valuation After Weaker 2025 Results And Dividend Cut

Labrador Iron Ore Royalty (TSX:LIF) is back on investors’ radar after 2025 results showed weaker royalty revenue and net income, along with a lower quarterly dividend that reflects pressure on cash flows. See our latest analysis for Labrador Iron Ore Royalty. The share price reaction has been quite sharp, with a 1 day share price return of a 3.16% decline and a 7 day share price return of a 9.16% decline, as the weaker 2025 results, reduced dividend and production challenges reset...
NYSE:COF
NYSE:COFConsumer Finance

Is Capital One’s 360 Savings Settlement Reshaping the Investment Case For Capital One Financial (COF)?

In early March 2026, Capital One Financial agreed to a proposed class action settlement over its 360 Savings accounts, including a US$425.00 million Settlement Fund and a commitment to align future 360 Savings interest rates with its 360 Performance Savings product, subject to court approval. The case highlights how differences in interest paid on similar-looking products and alleged disclosure gaps can create substantial legal, financial, and reputational repercussions for a large consumer...
TSX:FTS
TSX:FTSElectric Utilities

Assessing Fortis (TSX:FTS) Valuation As Analyst Upgrades And Options Activity Shift Expectations

Fortis (TSX:FTS) is back in focus after a recent upgrade in analyst rankings and a spike in options implied volatility, as traders and analysts react to refreshed earnings forecasts and shifting expectations. See our latest analysis for Fortis. At around CA$79.92, Fortis’s steady 12.17% year to date share price return and 28.34% one year total shareholder return suggest momentum has been building as investors respond to upgraded earnings views and heightened options market expectations. If...
NasdaqGS:SHC
NasdaqGS:SHCLife Sciences

Why Sotera Health (SHC) Is Down 8.5% After a $382 Million Share Sale And What's Next

Sotera Health recently completed a follow-on equity offering of US$381.75 million, issuing 25,000,000 common shares at US$15.27 each, boosting its capital base but increasing its share count. This fresh equity capital gives Sotera Health more financial flexibility to fund growth projects or reduce debt, while shareholders weigh the impact of dilution. Next, we'll examine how this sizeable equity raise and resulting dilution could reshape Sotera Health's investment narrative going...
TSE:8473
TSE:8473Capital Markets

A Look At SBI Holdings (TSE:8473) Valuation After Dividend Hike And ¥50b Share Buyback

Why SBI Holdings (TSE:8473) just moved its dividend goalposts SBI Holdings (TSE:8473) has raised its year end dividend forecast to ¥75 per share and highlighted a completed ¥50b share buyback, following a board decision tied to profits in its Financial Services Business. See our latest analysis for SBI Holdings. The updated dividend and completed ¥50b buyback come after a weaker run in the share price, with a 30 day share price return of 17.6% and a year to date return of 14.26%. This...
NasdaqGS:SFNC
NasdaqGS:SFNCBanks

Simmons First Earnings Beat Sparks Questions On Value And Dividend Support

Simmons First National (NasdaqGS:SFNC) reported quarterly results that exceeded revenue and EPS expectations. The bank highlighted resilient operations and solid performance within its regional banking footprint. The update adds fresh information on the company’s current business momentum that has not been reflected in recent coverage. Simmons First National, trading at $18.61, has delivered a quarter that came in ahead of both revenue and earnings forecasts, which puts a fresh spotlight on...
SEHK:1877
SEHK:1877Biotechs

Shanghai Junshi Biosciences SEHK 1877 Valuation After Mixed Recent Share Performance And DCF Upside Potential

Context for Shanghai Junshi Biosciences after recent share performance Shanghai Junshi Biosciences (SEHK:1877) has seen mixed share performance recently, with a small gain over the past week but declines over the past month and past 3 months, drawing attention to how its fundamentals line up. For investors tracking the stock longer term, the shares show a negative total return over 3 and 5 years, while the 1 year total return is positive. This can make current pricing and expectations...
NasdaqGS:WOOF
NasdaqGS:WOOFSpecialty Retail

Is It Time To Reconsider Petco Health and Wellness Company (WOOF) After The Recent Share Price Surge

This article examines whether Petco Health and Wellness Company, at around US$3.62, may represent a bargain or a value trap by exploring what the current share price might indicate about the business. The stock has recently experienced sharp moves, with returns of 52.1% over the last 7 days, 44.2% over the last 30 days, 27.0% year to date and 51.5% over the last year. However, the 3 year and 5 year returns show declines of 63.1% and 84.4%, which tells a very different story. These swings...
NYSE:ORI
NYSE:ORIInsurance

Old Republic Leadership Shift And Valuation Gap As Wordekemper Takes Helm

Old Republic International (NYSE:ORI) has appointed Doug Wordekemper as CEO of Old Republic Professional. The move is part of a broader organizational leadership change within the Professional division. The appointment brings a leader with extensive industry experience into a key role overseeing the Professional business. Old Republic International, through its Professional division, focuses on specialty insurance solutions for professional liability and related risks. Leadership changes in...
TSE:5844
TSE:5844Banks

Kyoto Financial Group (TSE:5844) Valuation After Earnings Upgrade Special Dividend And Expanded Buyback

Kyoto Financial Group Inc (TSE:5844) has drawn investor attention after sharply raising its earnings guidance, funded by large gains on equity sales, and pairing that move with a special dividend and expanded share buyback plan. See our latest analysis for Kyoto Financial GroupInc. The flurry of guidance upgrades, special dividend plans and the expanded buyback has coincided with strong recent momentum, with a 30 day share price return of 15.21% and a 1 year total shareholder return of...
NasdaqCM:KARO
NasdaqCM:KAROSoftware

Karooooo (NasdaqCM:KARO) Valuation Check As Cartrack Crosses Two Million Subscriber Milestone

Subscriber milestone puts Karooooo (KARO) in focus Cartrack, a subsidiary of Karooooo (KARO), has surpassed two million active subscribers in South Africa. This milestone puts the group’s mobility SaaS model and customer-focused execution firmly on investors’ radar. See our latest analysis for Karooooo. Karooooo’s latest subscriber milestone lands after a period where the share price has moved steadily rather than sharply, with a 5.69% year to date share price return and a 19.93% one year...
NYSE:WEX
NYSE:WEXDiversified Financial

Is WEX (WEX) Offering Value After Recent Share Price Volatility And Mixed Valuation Signals

If you are wondering whether WEX at around US$159.95 is priced fairly or offering value, you are not alone. This article is built to help you assess that question using several valuation tools. The stock has been relatively mixed recently, with a 7.8% return year to date and 3.8% over the last year, alongside a 4.3% decline over the past week and a 1.4% gain over the last 30 days. These movements can change how the market is thinking about its risk and opportunity. Recent coverage has...
TSX:CPX
TSX:CPXRenewable Energy

Does Capital Power’s 2025 Profit Drop And Steady Dividend Redefine The Bull Case For TSX:CPX?

Capital Power Corporation has reported its full-year 2025 results, with sales of CA$3,615 million and net income of CA$160 million, while also affirming a quarterly common dividend of CA$0.6910 per share and declaring dividends on several series of preferred shares. The sharp decrease in net income and earnings per share from continuing operations compared with the prior year contrasts with the company’s continued dividend payments, raising questions about how management is balancing...
ASX:EQR
ASX:EQRMetals and Mining

EQ Resources (ASX:EQR) H1 Loss Narrows Sharply, Testing Bearish Profitability Narratives

EQ Resources (ASX:EQR) has reported H1 2026 revenue of A$44.0 million with a basic EPS loss of A$0.0017, while trailing twelve month figures show revenue of A$75.4 million and a basic EPS loss of A$0.0067. The company has seen revenue move from A$34.8 million and a basic EPS loss of A$0.0118 in H1 2025 to A$31.5 million and a basic EPS loss of A$0.0060 in H2 2025, before reaching the latest H1 2026 levels. This sets up a story where growing sales are still being weighed against ongoing...
TSX:III
TSX:IIIMetals and Mining

Imperial Metals (TSX:III) Is Down 6.0% After Record 2025 Earnings And Red Chris Progress - Has The Bull Case Changed?

Imperial Metals Corporation recently reported its full-year 2025 results, with sales rising to C$691.78 million and net income reaching C$153.78 million, lifting basic earnings per share from continuing operations to C$0.91. Alongside record revenue and a stronger balance sheet, the company highlighted higher-end gold and copper production and continued progress on the Red Chris block cave expansion project. We’ll now consider how this combination of record revenue and advancing Red Chris...
NYSE:USPH
NYSE:USPHHealthcare

A Look At U.S. Physical Therapy’s Valuation As Shares Pull Back And P/E Stands At 53.9x

Setting the scene on U.S. Physical Therapy With no fresh headline event driving U.S. Physical Therapy (USPH) today, investors are left weighing a share price of $76.83 alongside recent return figures and the company’s latest reported revenue and net income. See our latest analysis for U.S. Physical Therapy. The recent share price pullback, including a 1-day share price return of 1.35% decline and a 30-day share price return of 11.63% decline, sits alongside a 1-year total shareholder return...
TSE:4967
TSE:4967Personal Products

Assessing Kobayashi Pharmaceutical (TSE:4967) Valuation After Oasis Management’s Governance Challenge

Governance dispute focuses attention on Kobayashi Pharmaceutical Oasis Management’s public campaign against Kobayashi Pharmaceutical (TSE:4967) and its move to a Company with an Audit and Supervisory Committee has pushed the company’s governance structure and board oversight firmly into the spotlight for shareholders. See our latest analysis for Kobayashi Pharmaceutical. The governance dispute has arrived after a period where the 90 day share price return of 7.41% contrasts with a weaker 3...
ENXTAM:KPN
ENXTAM:KPNTelecom

Does Twilio–Google RCS Partnership Make KPN the Backbone of Dutch Business Messaging (ENXTAM:KPN)?

At Mobile World Congress in March 2026, Twilio announced a partnership with KPN Netherlands and Google to roll out nationwide Rich Communication Services (RCS) Business Messaging across all major Dutch mobile operators, with Android support at launch and broader device coverage expected in 2026. This collaboration places KPN at the core of the Netherlands’ business messaging infrastructure, enabling enterprises to use richer, measurable and verified communications within native messaging...
NasdaqGS:SVCO
NasdaqGS:SVCOSoftware

Is Silvaco Group’s (SVCO) New MIPI IP Rollout Enough To Reframe Its Loss-Making Profile?

In March 2026, Silvaco Group, Inc. completed a follow-on at-the-market US$15 million common stock offering and reported full-year 2025 revenue of US$63.06 million with a net loss of US$41.21 million, alongside guidance for first-quarter 2026 revenue of US$15 million to US$19 million. A few days earlier, the company also announced the immediate availability of Mixel MIPI Production Ready Offerings, broadening its silicon-proven mixed-signal interface IP portfolio across advanced process nodes...
NasdaqGM:EH
NasdaqGM:EHAerospace & Defense

Did EHang’s Q4 Profit Amid Full-Year Losses Just Shift EHang Holdings’ (EH) Investment Narrative?

EHang Holdings Limited reported its fourth-quarter 2025 results on March 12, 2026, with sales rising to CNY 243.78 million and quarterly net income reaching CNY 10.49 million, while full-year 2025 revenue increased to CNY 509.50 million alongside a full-year net loss of CNY 230.54 million. The shift from a quarterly net loss in the prior year to profitability in Q4 2025, even as the full year remained loss-making, highlights a meaningful improvement in operating performance and cost...
NasdaqGM:CRVS
NasdaqGM:CRVSBiotechs

A Look At Corvus Pharmaceuticals (CRVS) Valuation After Recent Share Price Swings

Corvus Pharmaceuticals stock moves after recent performance swings Corvus Pharmaceuticals (CRVS) has been drawing fresh attention as its share price reflected sharp recent moves, including a 4.3% decline over the past day and a month return that is roughly 17.9% lower. See our latest analysis for Corvus Pharmaceuticals. Even with the latest 4.3% one day share price decline and a softer 30 day share price return of 17.9%, Corvus Pharmaceuticals still shows strong upward momentum, with a 90 day...